Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Cenap Güngör

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5173-9492; OpenAlex author ID A5038557646. Sources: OpenAlex.

Their work

Papers
21 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 4 papers · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 21

  1. RARRES1 marks an immune-cold, chemoresistance-associated malignant epithelial subpopulation enriched in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00262-026-04361-8↗
  2. Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08979-z↗
  3. Development of a hypoxia-responsive macrophage prognostic model using single-cell and bulk RNA sequencing in pancreatic cancer. Last author DOI 10.1371/journal.pone.0322618↗
  4. Unmasking metabolic dependencies in pancreatic cancer: aberrant polyamine synthesis as a promising new therapeutic target. Last author DOI 10.1038/s41392-023-01662-7↗
  5. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05728-y↗
  6. The Survival Effect of Radiotherapy on Stage IIB/III Pancreatic Cancer Undergone Surgery in Different Age and Tumor Site Groups: A Propensity Scores Matching A… Last author DOI 10.3389/fonc.2022.799930↗
  7. The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC. Last author DOI 10.3390/cancers14163998↗
  8. Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers14184405↗
  9. The survival impact of palliative radiotherapy on synchronous metastatic pancreatic ductal adenocarcinoma: metastatic site can serve for radiotherapy-decision. Co-author DOI 10.7150/jca.64800↗
  10. Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer. Co-author DOI 10.1093/glycob/cwab088↗
  11. A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy. Last author DOI 10.7150/jca.57768↗
  12. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Co-author DOI 10.1002/ijc.32567↗
  13. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis. Co-author DOI 10.1186/s13014-020-01561-z↗
  14. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis. Last author DOI 10.12659/msm.921515↗
  15. HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer. Co-author DOI 10.1007/s10495-016-1332-4↗
  16. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv387↗
  17. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0386-1↗
  18. Pancreatic cancer. Co-author DOI 10.1111/bph.12401↗
  19. ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0716↗
  20. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer. Last author DOI 10.1158/1541-7786.mcr-13-0467↗
  21. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-11-0036↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gerrit Wolters‐Eisfeld · 9 shared papers, 2014–2026 · strength 1.32
  2. Yuqiang Li · 7 shared papers, 2020–2025 · strength 1.16
  3. Thilo Hackert · 4 shared papers, 2016–2026 · strength 1.00
  4. Heming Ge · 4 shared papers, 2022–2026 · strength 0.98
  5. Jakob Robert Izbicki · 11 shared papers, 2011–2025 · strength 0.88
  6. Tarik Ghadban · 3 shared papers, 2017–2026 · strength 0.57
  7. Faik Güntac Uzunoglu · 5 shared papers, 2014–2025 · strength 0.55
  8. Maximilian Bockhorn · 8 shared papers, 2011–2021 · strength 0.45
  9. Dan Wang · 3 shared papers, 2020–2022 · strength 0.44
  10. Marianne Sinn · 3 shared papers, 2022–2025 · strength 0.43
  11. Leonie Konczalla · 3 shared papers, 2020–2025 · strength 0.37
  12. Bianca T. Hofmann · 5 shared papers, 2014–2021 · strength 0.33
  13. Danmei Zhang · 2 shared papers, 2023–2025 · strength 0.29
  14. Nicola Gagliani · 2 shared papers, 2023–2025 · strength 0.29
  15. Marija Trajkovic‐Arsic · 2 shared papers, 2023–2025 · strength 0.29
  16. Joseph Tintelnot · 2 shared papers, 2023–2025 · strength 0.29
  17. Jens Thomas Siveke · 2 shared papers, 2023–2025 · strength 0.29
  18. Alec C. Kimmelman · 2 shared papers, 2023–2025 · strength 0.29
  19. Stefan Hubert Boeck · 2 shared papers, 2023–2025 · strength 0.29
  20. Dan Wang · 2 shared papers, 2021–2022 · strength 0.27
  21. Matthias Reeh · 2 shared papers, 2017–2022 · strength 0.26
  22. Christine Nitschke · 2 shared papers, 2021–2022 · strength 0.25
  23. Kai A. Bachmann · 2 shared papers, 2014–2021 · strength 0.16
  24. Biaoxiang Xu · 1 shared paper, 2022 · strength 0.15
  25. Zhongyi Zhou · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.